Download File - JOHN J. HADDAD, Ph.D.

Peptide-Based Active Immunotherapy in Cancer 125
24. Di Cristina M, Minenkova O, Pavoni E, et al. A novel approach for identification of
tumor-associated antigens expressed on the surface of tumor cells. Int J Cancer 2006;
120:1293–1303.
25. Furukawa K, Hamamura K, Aixinjueluo W. Biosignals modulated by tumorassociated
carbohydrate antigens: novel targets for cancer therapy. Ann N Y Acad
Sci 2006; 1086:185–198.
26. Boss CN, Grunebach F, Brauer K, et al. Identification and characterization of T-cell
epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer
Res 2007; 13(11):3347–3355.
27. Kawahara M, Hori T, Matsubara Y, et al. Identification of HLA class I-restricted
tumor-associated antigens in adult T cell leukemia cells by mass spectrometric
analysis. Exp Hematol 2006; 34(11):1496–1504.
28. Greiner J, Schmitt M, Li L, et al. Expression of tumor-associated antigens in acute
myeloid leukemia: implications for specific immunotherapeutic approaches. Blood
2006; 108(13):4109–4117.
29. Toes REM, Ossendorp F, Offringa R, et al. CD4 T cells and their role in antitumor
immune responses. J Exp Med 1999; 189(5):753–756.
30. Baxevanis CN, Voutsas IF, Tsitsilonis OE, et al. Tumor-specific CD4þ T lymphocytes
from cancer patients are required for optimal induction of cytotoxic T cells
against the autologous tumor. J Immunol 2000; 164(7):3902–3912.
31. Zarour HM, Kirkwood JM, Kierstead LS, et al. Melan-A/MART-1(51-73) represents
an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive
CD4(þ) T cells. Proc Natl Acad Sci U S A 2000; 97(1):400–405.
32. Klyushnenkova EN, Kouiavskaia DV, Kodak JA, et al. Identification of HLA-
DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
Prostate 2007; 67(10):1019–1028.
33. Schulz M, Zinkernagel RM, Hengartner H. Peptide-induced antiviral protection by
cytotoxic T cells. Proc Natl Acad Sci U S A 1991; 88:991–993.
34. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in
melanoma patients immunized with a peptide from MART-1/Melan A [see comments].
Cancer J Sci Am 1997; 3:37–44.
35. Lipford GB, Hoffman M, Wagner H, et al. Primary in vivo responses to ovalbumin.
Probing the predictive value of the Kb binding motif. J Immunol 1993; 150:
1212–1222.
36. Zhou FR, Rouse BT, Huang L. Prolonged survival of thymoma-bearing mice after
vaccination with a soluble protein antigen entrapped in liposomes: a model study.
Cancer Res 1992; 52:6287–6291.
37. Mossman SP, Evans LS, Fang H, et al. Development of a CTL vaccine for Her-2/neu
using peptide-microspheres and adjuvants. Vaccine 2005; 23(27):3545–3554.
38. Zhou F, Rouse BT, Huang L. Induction of cytotoxic T lymphocytes in vivo with
protein antigen entrapped in membranous vehicles. J Immunol 1992; 149:1599–1604.
39. Harty JT, Bevan MJ. CD8þ T cells specific for a single nonamer epitope of Listeria
monocytogenes are protective in vivo. J Exp Med 1992; 175:1531–1538.
40. Noguchi Y, Chen YT, Old LJ. A mouse mutant p53 product recognized by CD4þ
and CD8þ T cells. Proc Natl Acad Sci U S A 1994; 91:3171–3175.
41. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells
serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15:
94–103.